What laboratory tests are recommended for routine colorectal cancer screening in an average-risk adult aged 45‑75?

Laboratory Tests for Colorectal Cancer Screening

No laboratory blood tests are recommended for routine colorectal cancer screening in average-risk adults aged 45-75. Blood-based tests such as SEPT9 and Shield are explicitly excluded from all major screening guidelines because they lack demonstrated mortality benefit. 1, 2, 3

Guideline-Endorsed Screening Tests (Not Laboratory Tests)

The following are the only recommended screening modalities for average-risk adults:

First-Tier Options (Strongest Evidence)

• Colonoscopy every 10 years – provides the highest sensitivity for detecting and removing precancerous polyps during the same procedure, offering 10 years of protection after a negative exam. 1, 2

• Annual fecal immunochemical test (FIT) – a stool-based test (not a blood test) with 75-100% sensitivity for cancer detection and 95% specificity, requiring annual testing and follow-up colonoscopy for positive results. 4, 1, 2

Acceptable Alternative Options

• Multitarget stool DNA test (Cologuard) every 3 years – a stool-based test with 87% specificity, endorsed as an acceptable alternative when first-tier tests are declined. 4, 2, 3

• CT colonography every 5 years – a radiologic imaging test requiring bowel preparation but no sedation. 4, 2

• Flexible sigmoidoscopy every 5-10 years – an endoscopic examination of the distal colon only. 4, 2

Why Blood Tests Are Not Recommended

• The USPSTF explicitly excludes serum, urine, and blood-based circulating tumor DNA (ctDNA) tests from colorectal cancer screening recommendations due to limited evidence and lack of proven mortality reduction. 2, 3

• The American College of Physicians recommends against serum screening tests for colorectal cancer. 2

• The U.S. Multi-Society Task Force recommends against the SEPT9 blood assay for screening. 2

• Shield and other blood-based tests are not included in any major guideline (American Cancer Society 2018, USPSTF 2021, U.S. Multi-Society Task Force 2017) and remain investigational without demonstrated clinical benefit. 3

Age-Specific Screening Recommendations

• Begin screening at age 45 for average-risk adults (qualified recommendation) or at age 50 (strong recommendation with highest-quality evidence). 4

• Continue screening through age 75 in adults with life expectancy >10 years. 4

• Individualize screening for ages 76-85 based on prior screening history, overall health, and life expectancy >10 years. 4

• Discontinue screening after age 85 or when life expectancy is <10 years, as harms outweigh benefits. 4

Critical Implementation Points

• All positive results from stool-based or imaging tests mandate timely diagnostic colonoscopy – this is non-negotiable and integral to the screening process. 4, 1, 2

• Symptomatic patients require immediate diagnostic colonoscopy, not screening tests – alarm symptoms include rectal bleeding, unexplained weight loss, change in bowel habits, or iron-deficiency anemia. 1, 2

• High-risk patients (family history of colorectal cancer, inflammatory bowel disease, hereditary syndromes) require colonoscopy starting at age 40 or 10 years before the youngest affected relative's diagnosis, not stool-based or blood tests. 4, 1, 2

Common Pitfalls to Avoid

• Do not order blood-based screening tests such as SEPT9 or Shield – they are not guideline-endorsed and have no proven mortality benefit. 2, 3

• Do not use screening tests in symptomatic patients – they require diagnostic colonoscopy regardless of any test results. 1, 2

• Do not continue screening past age 75 in patients with adequate prior negative screening – harms increasingly outweigh benefits with advancing age. 4